Literature DB >> 24855211

Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia.

David C Linch1, Robert K Hills2, Alan K Burnett2, Asim Khwaja1, Rosemary E Gale1.   

Abstract

Some studies have suggested that cases of acute myeloid leukemia (AML) with low levels of FLT3 internal tandem duplications (FLT3(ITD)) do not have a worse prognosis if there is a concomitant NPM1 mutation, although this is controversial. To clarify this therapeutically important issue, we have analyzed FLT3(ITD) and NPM1(MUT) levels in 1609 younger adult cases of cytogenetically intermediate-risk AML. The cumulative incidence of relapse was increased in NPM1(MUT) cases by the presence of a FLT3(ITD), but did not differ markedly according to FLT3(ITD) level. This remained true when allowance was made for poor leukemic cell purity by adjustment of the FLT3(ITD) level to the measured NPM1(MUT) level. If consolidation therapies are to be determined by relapse risk, then NPM1(MUT) cases with low-level FLT3(ITD) should not be considered as good risk without further studies. AML 12 and AML 15 are registered at http://www.controlled-trials.com under ISRCTN17833622 and ISRCTN17161961, respectively.
© 2014 by The American Society of Hematology.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24855211     DOI： 10.1182/blood-2014-02-554667

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  43 in total

Review 1.  Targeting polo-like kinase 1 in acute myeloid leukemia.

Authors:  Joseph M Brandwein
Journal:  Ther Adv Hematol       Date:  2015-04

2.  Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia.

Authors:  Betül Oran; Jorge Cortes; Amer Beitinjaneh; Hsiang-Chun Chen; Marcos de Lima; Keyur Patel; Farhad Ravandi; Xuemei Wang; Mark Brandt; Borje S Andersson; Stefan Ciurea; Fabio P Santos; Leandro de Padua Silva; Elizabeth J Shpall; Richard E Champlin; Hagop Kantarjian; Gautam Borthakur
Journal:  Biol Blood Marrow Transplant       Date:  2016-04-04       Impact factor: 5.742

3.  Acquired isodisomy on chromosome 13 at diagnosis results in impaired overall survival in patients with FLT3-ITD mutant acute myeloid leukaemia.

Authors:  J C T Loke; S Akiki; J Borrow; J Ewing; S W Bokhari; D Chandra; J Arrazi; P Hazlewood; K Arthur; J Walsh; Y Membwange; F A Wandroo; A Watts; A Borg; K Brock; P Ferguson; C Craddock; M Griffiths; M Raghavan
Journal:  Leukemia       Date:  2015-06-19       Impact factor: 11.528

4.  Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio.

Authors:  J Versluis; F E M In 't Hout; R Devillier; W L J van Putten; M G Manz; M-C Vekemans; M-C Legdeur; J R Passweg; J Maertens; J Kuball; B J Biemond; P J M Valk; B A van der Reijden; G Meloni; H C Schouten; E Vellenga; T Pabst; R Willemze; B Löwenberg; G Ossenkoppele; F Baron; G Huls; J J Cornelissen
Journal:  Leukemia       Date:  2016-06-24       Impact factor: 11.528

Review 5.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Authors:  Hartmut Döhner; Elihu Estey; David Grimwade; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Hervé Dombret; Benjamin L Ebert; Pierre Fenaux; Richard A Larson; Ross L Levine; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel Sanz; Jorge Sierra; Martin S Tallman; Hwei-Fang Tien; Andrew H Wei; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2016-11-28       Impact factor: 22.113

6.  Transcriptome analysis offers a comprehensive illustration of the genetic background of pediatric acute myeloid leukemia.

Authors:  Norio Shiba; Kenichi Yoshida; Yusuke Hara; Genki Yamato; Yuichi Shiraishi; Hidemasa Matsuo; Yusuke Okuno; Kenichi Chiba; Hiroko Tanaka; Taeko Kaburagi; Masanobu Takeuchi; Kentaro Ohki; Masashi Sanada; Jun Okubo; Daisuke Tomizawa; Tomohiko Taki; Akira Shimada; Manabu Sotomatsu; Keizo Horibe; Takashi Taga; Souichi Adachi; Akio Tawa; Satoru Miyano; Seishi Ogawa; Yasuhide Hayashi
Journal:  Blood Adv       Date:  2019-10-22

7.  Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes.

Authors:  Prajwal C Boddu; Tapan M Kadia; Guillermo Garcia-Manero; Jorge Cortes; Mansour Alfayez; Gautam Borthakur; Marina Konopleva; Elias J Jabbour; Naval G Daver; Courtney D DiNardo; Kiran Naqvi; Musa Yilmaz; Nicholas J Short; Sherry Pierce; Hagop M Kantarjian; Farhad Ravandi
Journal:  Cancer       Date:  2018-12-06       Impact factor: 6.860

Review 8.  Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia.

Authors:  C Michel Zwaan; Edward A Kolb; Dirk Reinhardt; Jonas Abrahamsson; Souichi Adachi; Richard Aplenc; Eveline S J M De Bont; Barbara De Moerloose; Michael Dworzak; Brenda E S Gibson; Henrik Hasle; Guy Leverger; Franco Locatelli; Christine Ragu; Raul C Ribeiro; Carmelo Rizzari; Jeffrey E Rubnitz; Owen P Smith; Lillian Sung; Daisuke Tomizawa; Marry M van den Heuvel-Eibrink; Ursula Creutzig; Gertjan J L Kaspers
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

9.  Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study.

Authors:  Akira Shimada; Yuka Iijima-Yamashita; Akio Tawa; Daisuke Tomizawa; Miho Yamada; Shiba Norio; Tomoyuki Watanabe; Takashi Taga; Shotaro Iwamoto; Kiminori Terui; Hiroshi Moritake; Akitoshi Kinoshita; Hiroyuki Takahashi; Hideki Nakayama; Katsuyoshi Koh; Hiroaki Goto; Yoshiyuki Kosaka; Akiko Moriya Saito; Nobutaka Kiyokawa; Keizo Horibe; Yusuke Hara; Kentaro Oki; Yasuhide Hayashi; Shiro Tanaka; Souichi Adachi
Journal:  Int J Hematol       Date:  2018-01-12       Impact factor: 2.490

10.  Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia.

Authors:  Masahiro Sakaguchi; Hiroki Yamaguchi; Yuho Najima; Kensuke Usuki; Toshimitsu Ueki; Iekuni Oh; Sinichiro Mori; Eri Kawata; Nobuhiko Uoshima; Yutaka Kobayashi; Shinichi Kako; Kenji Tajika; Seiji Gomi; Katsuhiro Shono; Kensuke Kayamori; Masao Hagihara; Junya Kanda; Hitoji Uchiyama; Junya Kuroda; Naoyuki Uchida; Yasushi Kubota; Shinya Kimura; Saiko Kurosawa; Nana Nakajima; Atsushi Marumo; Ikuko Omori; Yusuke Fujiwara; Shunsuke Yui; Satoshi Wakita; Kunihito Arai; Tomoaki Kitano; Kazuhiko Kakihana; Yoshinobu Kanda; Kazuteru Ohashi; Takahiro Fukuda; Koiti Inokuchi
Journal:  Blood Adv       Date:  2018-10-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.